Vivani Medical, Inc. (NasdaqCM: VANI) is a clinical-stage biopharmaceutical company developing miniature, ultra-long-acting subdermal implants using its NanoPortal platform. Because it has a small analyst following, coverage is limited but consistent. Three current, individually attributed targets were reviewed:
The arithmetic mean of these three targets is about $3.83, which rounds to a central target of $3.80. The low-to-high range is narrow at $3.50–$4.00, and all three ratings are Buy-equivalent, giving the group a bullish skew. That unanimity partly reflects the analysts' focus on the company's GLP-1 implant opportunity rather than a guarantee of performance. The H.C. Wainwright reduction from $4.00 to $3.50 is a modest, cautious revision worth noting, while Lake Street's initiation and Maxim's reiteration came after the Novo Nordisk evaluation agreement and SLIM-1 enrollment milestones.
VANI shares traded near $1.13 in late October 2026, with a 52-week range of roughly $0.92 to $1.81 and a market capitalization around $103 million. Reaching $3.80 would require a gain of about 236%, a very large move that would effectively triple the share price. The path would hinge on clinical execution: top-line results from the SLIM-1 Phase 1 trial of NPM-139, a semaglutide implant for chronic weight management, are expected in November 2026. Positive data on safety, tolerability, and pharmacokinetics could reposition the stock well above current levels, while a Phase 2 dose-ranging study is targeted for 2027. The company is pre-revenue, so the equity value is driven by binary clinical and partnership catalysts rather than earnings.
VANI is trading in the middle of its 52-week range after a run-up on the Novo Nordisk announcement and SLIM-1 dosing milestones. The $1.81 area marks the prior 52-week high and a key resistance zone that would need to be cleared before any move toward $3.80 becomes credible. On the downside, the $0.92–$1.00 region has acted as support, with $1.00 serving as a psychological level. Because the float is small and the stock is volatile (a five-year monthly beta near 3.3), technical levels can be tested quickly around binary news events.
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms may vary. The most important near-term catalyst is the SLIM-1 top-line data expected in November 2026, followed by the next quarterly earnings release (estimated around November 12, 2026), the completion of the Cortigent-ClearOne merger, and any update on the Novo Nordisk evaluation. Investors should also watch analyst revisions, cash runway commentary, and guidance toward the planned 2027 Phase 2 study.
AI Daily Buy/Sell Signals from Tickeron use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile, catalyst-driven name like VANI, these signals can help traders discover opportunities, monitor positions, and spot shifting trends more efficiently than manual review. Explore the AI Daily Buy/Sell Signals tool to bring automated insight into your own decision process.
The central target of $3.80 reflects the average of three Buy-rated analyst targets ($3.50–$4.00) and implies a very large, roughly 236% rise from the current price near $1.13. The bull case rests almost entirely on the NPM-139 semaglutide implant program, the Novo Nordisk evaluation agreement, and favorable upcoming SLIM-1 data. The bear case centers on early-stage clinical risk, an unprofitable pre-revenue model, likely future dilution, and intense competition in the GLP-1 space. Analysts are uniformly constructive but their targets cluster tightly, reflecting a high-conviction, high-risk view. Whether VANI can reach $3.80 will depend primarily on clinical results, partnership developments, and the company's ability to fund its pipeline — outcomes that remain uncertain and should be monitored closely rather than assumed.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, VANI has been loosely correlated with VTVT. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if VANI jumps, then VTVT could also see price increases.
| Ticker / NAME | Correlation To VANI | 1D Price Change % | ||
|---|---|---|---|---|
| VANI | 100% | +2.22% | ||
| VTVT - VANI | 60% Loosely correlated | -0.85% | ||
| AZR - VANI | 37% Loosely correlated | +0.27% | ||
| NKTX - VANI | 37% Loosely correlated | -15.09% | ||
| AXSM - VANI | 36% Loosely correlated | +5.23% | ||
| SCNI - VANI | 34% Loosely correlated | +7.03% | ||
More | ||||